Ripretinib Exhibits Better Tolerability Profile than Sunitinib in Advanced GIST Tumors
16490
post-template-default,single,single-post,postid-16490,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Ripretinib Exhibits Better Tolerability Profile than Sunitinib in Advanced GIST Tumors

Home > Blogs  > Ripretinib Exhibits Better Tolerability Profile than Sunitinib in Advanced GIST Tumors

27 Aug Ripretinib Exhibits Better Tolerability Profile than Sunitinib in Advanced GIST Tumors

Posted at 09:50h in Blogs by

In patients with advanced GIST who progressed on or were intolerant to first-line treatment with imatinib, ripretinib, a switch-control TKI, showed comparable median PFS as sunitinib, suggesting that ripretinib is active as second-line therapy for GIST. Additionally, ORR for patients receiving ripretinib in the KIT exon 11 population was higher compared with patients receiving sunitinib. Ripretinib demonstrated a more favorable safety profile and better responses on PRO measures than sunitinib. (Ref: Bauer S et al. J Clin Oncol. Aug 10, 2022)
#oncologyresearch #clinicalresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6969173938740310016

No Comments

Sorry, the comment form is closed at this time.